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Abstract
Background: In ovarian cancer, the role of estrogen receptors (ERs), particularly of ERβ, being suggested as tumor
suppressor in breast and prostate cancer, remains unclear. We examined the expression of nuclear and cytoplasmic
ERβ in ovarian cancer and correlated it with expression of ovarian cancer markers CA125, CEA and CA72–4, steroid
hormone receptors ERα and PR, cancer-associated genes EGFR, p53, HER2 and proliferation marker Ki-67. Additionally
we examined to what extent expression of ERβ and the other proteins affects survival of ovarian cancer patients.
Methods: We established a tissue microarray from 171 ovarian cancer patients and performed immunohistochemical
analyses of the mentioned proteins.
Results: Nuclear ERβ was detected in 47.31% of the ovarian cancer tissues and cytoplasmic expression of this receptor
was observed in 23.08%. Nuclear expression of ERβ was significantly decreased in the G3 subgroup compared to better
differentiated cancers (p < 0.01) and correlated with ovarian cancer markers CEA (95% CI 0.1598–0.4465; p < 0.0001)
and CA72–4 (95% CI 0.05953–0.3616; p < 0.01). Cytoplasmic ERβ expression correlated with EGFR levels (95% CI 0.
1059–0.4049; p < 0.001). ERα expression was associated with expression of CA125 and PR. Overall survival of patients
with tumors expressing cytoplasmic ERβ was significant longer compared to those with ERβ-negative ovarian cancer
(chi-square statistic of the log-rank, p < 0.05). Progression-free survival was dependent on expression of PR (chi-square
statistic of the log-rank, p < 0.05) and Ki-67 (p = 0.05).
Conclusions: Our data suggest an important, but distinct role of nuclear and cytoplasmic ERβ expression in ovarian
cancer and encourage further studies on its role in this cancer entity.
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Background
Ovarian cancer is the leading cause of death from a
gynecological malignancy in the developed world [1].
Ovarian cancers are influenced by steroid hormones.
Antiestrogenic treatment inhibits growth of ovarian can-
cer in vitro and in vivo [2–4]. Progesterone receptor
(PR) and ER expression are reported to be associated
with improved ovarian cancer survival, independent of
clinical prognostic factors, but these associations have
not been consistently repeated [5, 6]. In the clinical set-
ting antiestrogens are commonly used in patients with
relapsed ovarian cancers after multiple lines of cytostatic
therapies that have exhausted further treatment. Avail-
able data remains inconclusive, mostly due to heterogen-
eity of ovarian cancers and inadequate study settings as
low number of included patients, missing subgroup ana-
lyses and absent evaluation of ER expression. However,
use of tamoxifen and aromatase inhibitors have effects
in a certain subgroup of patients [7, 8].
Previous studies clearly suggest a tumor suppressive
role of ERβ in ovarian cancer as it has been shown for
breast or prostate cancer [9–11]. Our group demon-
strated that ERβ reduces proliferation and migration, but
activates apoptosis of ovarian cancer cells [12] and that
specific ERβ-agonists significantly inhibit growth of dif-
ferent ovarian cancer cell lines [13]. Furthermore, our
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results from a phenotype-genotype association study
suggested that the single nucleotide polymorphism
rs3020449 in the promoter region of ESR2 gene might
affect progression of ovarian cancer [14].
ERβ is the predominant ER in normal ovarian tissue.
In ovarian cancer the expression of ERβ is significantly
lower and the ERα/ERβ ratio is significantly higher than
in normal ovarian tissue [15–17]. High expression of
ERβ in ovarian cancers is associated with a better
progression-free and overall survival [15, 17].
Ovarian cancer marker cancer antigen 125 (CA125) is
overexpressed in the majority of ovarian cancers and it
has been shown to be involved in the metastatic
process [18]. CA125 regulates cell adhesion by interact-
ing with mesothelin, galectin-1, E-cadherin and
β-catenin [18, 19]. Moreover, CA125 can promote pro-
liferation and migration [20]. Also for the broad
spectrum tumor marker carcinoembryonic antigen
(CEA) a regulative role of cell adhesion and thus an in-
fluence on metastasis of cancer cells has been suggested
[21]. Another antigen selectively expressed in ovarian
cancer is CA72–4. As it is highly detectable in all ovar-
ian cancer subtypes it is another effective tumor marker
in ovarian cancer [22]. However, its function in carcino-
genesis of ovarian cancer is still unknown.
Recently, it has been reported that a shuffle of ERβ be-
tween nucleus and cytoplasm plays important roles in
regulation of gene transcription, RNA maturation and
post-transcriptional control [23]. To further approach
the significance of subcellular ERβ localization in ovarian
cancer, we examined co-expression of nuclear and cyto-
plasmic ERβ with various cancer-associated genes and
steroid hormone receptors and tested to what extent re-
ceptor localization would affect survival of ovarian can-
cer patients.
Methods
Tissue samples
We included ovarian cancer samples collected in the De-
partment of Gynecology and Obstetrics of the University
of Regensburg. Caucasian women with sporadic ovarian
cancer and available information on grading, stage, and
histological subtype from 1995 to 2013 were included.
Data from the Tumor Centre Regensburg (Bavaria,
Germany), a high-quality population-based regional can-
cer registry of the districts of Upper Palatinate and Lower
Bavaria, were analysed. Mortality data were obtained from
regional registration offices. The institutional review board
“Ethikkommission der Universität Regensburg” approved
the retrospective study.
Tissue microarray and immunohistochemistry
The tissue microarray (TMA) was created using stand-
ard procedures that have been previously described [24].
From all patients included in this study, an experienced
pathologist evaluated H&E sections of tumor tissue and
representative areas were marked. From each tumor, one
single core was included in the final TMA. From these
areas, core biopsies on the corresponding paraffin blocks
were removed and transferred into the grid of a recipient
block according to a predesigned array of about 60 spec-
imens in each of five TMA paraffin blocks.
For immunohistochemistry, 4 μm sections of the TMA
blocks were incubated with the indicated antibodies
(Additional file 1) according to routine protocols in the
given dilutions, followed by incubation with an HRP-
conjugated secondary antibody and another incubation
with 3,3′-diaminobenzidine (DAB) as substrate, which
resulted in a brown-colored precipitate at the antigen
site. An experienced clinical pathologist evaluated im-
munohistochemical staining according to localization
and specificity. For steroid hormone receptors ERα, nu-
clear ERβ and PR, the immunoreactivity score (IRS) ac-
cording to Remmele et al. was used [25], wherein the
percentage of stained nuclei in a 5-tiered scale (0% = 0,
1–9% = 1, 10–50% = 2, 51–80% = 3 and 81–100% = 4) is
multiplied with the staining intensity on a 4-tiered scale
(no staining = 0, weak staining = 1, moderate staining = 2,
strong staining = 3), resulting in an IRS ranging between 0
(completely negative) and 12 (strongly positive).
Expression of proliferation marker Ki-67 using antibody
clone MIB-1 was assessed in the percentage of tumor cells
with positive nuclear staining. Her2/neu expression was
scored according to the DAKO score routinely used for
breast cancer cases. EGFR was scored according to
Spaulding et al. [26] on a 4-tiered scale from 0 to 3. EGFR
expression was considered present when membranous
staining was stronger than unspecific or cytoplasmic back-
ground staining, irrespective of complete or incomplete
circumferential staining. Score 1 was defined as incom-
plete and weak membranous staining in > 1% of tumor
cells, score 2 as moderate staining and score 3 as strong
membranous staining in > 1% of tumor cells.
For p53 and polyclonal CEA, the “quickscore” was used,
where results are scored by multiplying the percentage of
positive cells (P) by the intensity (I) according to the for-
mula: Q = P x I; maximum= 300 [27]. CA-125 and cyto-
plasmic ERβ were described as positive or negative,
irrespective of staining intensity. CA72–4 expression was
assessed on a 4-tiered scale, wherein no expression
equaled score 0, weak cytoplasmic and/or membranous
staining in > 1% of tumor cells equaled score 1, moderate
staining score 2 and strong staining corresponded to score
3 (if > 50% of tumor cells, otherwise score 2).
Statistical analysis
Statistical analysis was performed using GraphPad
Prism 5® (GraphPad Software, Inc., La Jolla, CA, USA). The
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non-parametric Kruskal-Wallis rank-sum test was used for
testing differences in receptor expression among three or
more groups. For pairwise comparison the nonparametric
Mann-Whitney-U rank-sum test was used. Correlation
analysis was performed using the Spearman correlation co-
efficient. The chi-square statistic of the log-rank was used
to investigate differences between survival curves. P-values
below 0.05 were considered statistically significant.
Results
Characteristics of included patients and their tumors
In this study, we used tissue from 171 Caucasian women
with sporadic ovarian cancer and a median age at diag-
nosis of 63.5 years (range 29–91). The histopathological
characteristics of the patients are shown in Table 1.
63.7% of the tumors were diagnosed in FIGO (Inter-
national Federation of Gynaecologists and Obstetricians)
stages III and IV (38.6 and 25.15, respectively). Most of
the tumors were serous (78.36%) and 64.3% of the tumors
were grade 3. Median follow-up time was 1180 days. 80
relapses and 62 deaths were documented. Median relapse
free survival was 1044 days and median overall survival
was 1673 days.
Expression of steroid hormone receptors in ovarian
cancer tissue
Nuclear ERβ was expressed in 47.31%, and cytoplasmic
expression of this receptor was detected in 23.08% of
ovarian cancer specimens (Fig. 1, Table 2). Nuclear ERβ
expression was found to be lower in the subgroup of G3
tumors than in better differentiated cancer specimens
(p < 0.05) (Table 3, Fig. 2). ERα was expressed in 70.35%
of all ovarian cancer samples, whereas PR was detected
in 33.33% of the samples. PR expression was higher in
FIGO I + II tumors than in the FIGO III + IV subgroup
(p < 0.05) (Table 3). A significantly higher expression of
PR was also found in tumors without invasion of lymph-
atic vessels compared to those with invasion. As serous
ovarian cancer was the most common histological sub-
type, we further analysed this group and found similar
rates of positive receptor expression. The subgroup of
G3-tumors and those of stage III and IV also did not
show significant differences. Further subgroup-analyses
as well as analyses of other variables as residual disease
after initial surgery, age at diagnosis or invasion of ven-
ous vessels did not reveal significant results because of
the low number of included cases.
Nuclear ERβ expression levels positively correlate with
expression of CEA and CA72–4
Subsequently, we investigated correlations between the
expression levels of ERβ and ERα, PR, CA125, CEA,
CA72–4, EGFR, HER2, Ki-67 and p53.
Table 1 Staging and histopathological characteristics of ovarian
cancer cases
Characteristics Number of patients (%)
Ovarian cancer patients 171
FIGO stage
FIGO I 23 (13.45)
FIGO II 9 (5.26)
FIGO III 66 (38.60)
FIGO IV 43 (25.15)
unknown 30 (17.54)
Histological subtype
serous 134 (78.36)
mucinous 6 (3.51)
endometrioid 10 (5.85)
clear cell 5 (2.92)
undifferentiated 16 (9.36)
Histological grade
G2 47 (27.49)
G3 110 (64.33)
unknown 14 (8.19)
Fig. 1 Immunohistochemical staining patterns of ERβ: a Moderate to
strong nuclear expression of ERβ. b Weak cytoplasmic expression of ERβ
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We found a highly significant positive correlation be-
tween nuclear ERβ and ovarian cancer marker CEA
(p < 0.0001; 95% confidence interval (CI) 0.1598–
0.4465) (Table 4). This significant correlation was also
found in the serous subtype (p < 0.0001; 95% CI
0.1770–0.4930). Moreover, we observed a highly signifi-
cant correlation between nuclear ERβ and CA72–4
(p < 0.01; 95% CI 0.05953–0.3616) in all ovarian cancer
specimens as well as in the serous subtype (p < 0.01;
95% CI 0.08939 to 0.4225).
Cytoplasmic ERβ expression levels positively correlate
with EGFR expression
Additionally, we observed a significant correlation between
cytoplasmic ERβ expression levels with expression of EGFR
(p < 0.001; 95% CI 0.1059–0.4049). In serous ovarian can-
cers this effect reappeared (p < 0.01; 95% CI 0.06–0.4016)
and we observed a significant correlation with PR expres-
sion (p < 0.05; 95% CI 0.02307–0.3688) (Table 5).
ERα expression levels correlate with expression of CA125
and PR
Examining the correlation of ERα with different markers,
we found a significant correlation between this receptor
and CA125 (p < 0.001; 95% CI 0.1188–0.4068), which was
also observed in the serous subtype (p < 0.05; 95% CI
0.03457–0.3702). The correlation between ERα and CA125
was also significant in the subgroups of G2 and G3 ovarian
cancers (p < 0.01; 95% CI 0.1431–0.6367 and p < 0.01; 95%
CI 0.0567–0.4210, respectively) (Additional file 2).
The expression of ERα significantly correlated with ex-
pression of PR (p < 0.0001; 95% CI 0.2143–0.4914),
which was also observed in the subgroup of serous ovar-
ian cancers (p < 0.0009; 95% CI 0.1188–0.4477),
Overall survival of patients expressing cytoplasmic ERβ is
significant longer compared to those of patients with
ERβ-negative tumors
Survival analyses revealed a significant longer overall
survival of patients with tumors expressing cytoplasmic
Table 2 Steroid hormone receptor expression in ovarian cancer: rate of expression of the indicated receptors
ERα ERβ (nuclear) ERβ (cytoplasmic) PR
All All 121/172 (70.35) 79/167 (45.04) 39/169 (23.08) 55/165 (33.33)
G2 33/47 (70.21) 29/46 (63.04) 12/46 (26.09) 15/47 (31.91)
G3 78/111 (70.27) 45/109 (41.28) 19/109 (17.43) 36/106 (33.96)
FIGO I + II 21/32 (70.54) 12/30 (40.00) 7/31 (22.58) 16/31 (51.61)
FIGO III + IV 79/112 (65.63) 45/100 (45.00) 7/31 (22.58) 31/108 (28.70)
Serous Serous 99/133 (74.44) 59/131 (49.62) 27/131 (20.61) 46/128 (35.94)
G2 23/31 (74.19) 18/31 (58.06) 9/31 (29.03) 11/31 (35.48)
G3 71/97 (73.20) 38/95 (40.00) 17/95 (17.89) 33/92 (35.87)
FIGO I + II 15/20 (75.00) 5/19 (26.32) 6/20 (30.00) 12/19 (63.16)
FIGO III + IV 70/96 (72.92) 45/95 (47.37) 19/92 (20.65) 28/92 (30.43)
Shown are the numbers of positive samples in relation to the total numbers of ovarian cancer cases of the subgroups analysed and the corresponding percentage
(in brackets)
Table 3 Steroid hormone receptor expression in ovarian cancer: mean receptor expression levels in all ovarian cancer specimens
ERα ERβ (nuclear) ERβ (cytoplasmic) PR
Mean p-value Mean p-value Mean p-value Mean p-value
G2 4.30 0.9464 1.72 0.0466 0.26 0.4424 2.19 0.9202
G3 4.06 1.07 0.17 1.19
FIGO I + II 3.97 0.9172 1.27 0.6752 0.23 0.9548 3.48 0.0202
FIGO III + IV 4.15 1.28 0.21 1.06
G2 4.26 0.9835 1.58 0.2049 0.29 0.4139 1.90 0.8961
G3 4.06 1.12 0.18 1.18
FIGO I + II 3.80 0.9338 0.79 0.2563 0.30 0.6205 3.37 0.0190
FIGO III + IV 4.10 1.31 0.21 1.05
A non-parametric Kruskal-Wallis rank-sum test was used for testing differences in receptor expression of estrogen receptor (ER) α, nuclear ERβ, cytoplasmic ERβ
and progesterone receptor (PR) among the groups. p-values < 0.05 were considered statistically significant (indicated by using bold font)
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ERβ compared to those having ERβ-negative tumors
(chi-square statistic of the log-rank, p < 0.05). Patients
with ovarian cancers not expressing cytoplasmic ERβ
had a median survival of 1628 days, whereas in the co-
hort with cytoplasmic ERβ expressing tumors, survival
was still more than 50% at the longest time point (haz-
ard ratio (HR) 1.842; 95% CI 1.040–3.264) (Fig. 3).
Longer progression-free survival of patients with ovarian
cancers expressing PR and with low Ki-67 expression
Patients with tumors expressing PR (IRS ≥ 1) had a sig-
nificant longer progression-free survival compared to
those with tumors not expressing PR (IRS 0) (chi-square
statistic of the log-rank, p < 0.05) (Fig. 4a). This signifi-
cant difference was also observed in the subgroup of ser-
ous ovarian cancers (data not shown). Progression-free
survival significantly differed in those patients with tu-
mors expressing Ki-67 by more than 14% (chi-square
statistic of the log-rank, p < 0.05) (Fig. 4b). This effect
also was visible in serous tumors (data not shown).
Discussion
Several studies showed a wide range of expression levels
of steroid hormone receptors in ovarian cancer [28–30].
In our study including 171 ovarian cancer cases, 70.35%
of all cases were ERα positive. This is in line with the
data of Lee et al. who found this receptor to be
expressed in 77.3% of all cases [30]. In other studies,
ERα was only expressed in 31.4–36% of ovarian cancer
specimens [28, 29]. These differences might be due to
different applied ERα antibodies detecting a specific set of
splice variants. Investigating ERβ expression reveals even
more difficulties as specific antibodies have not been avail-
able for a long time. Moreover, it is important to distin-
guish between nuclear and cytoplasmic ERβ expression as
their role in carcinogenesis differs [31, 32]. In our study,
nuclear ERβ was expressed in 49.62% and cytoplasmic ERβ
in only 20.61% of all cases. Other studies showed rates of
positive ERβ expression between 48 and 60% [28, 33]. In
the study of De Stefano et al. including 58 serous ovarian
cancers nuclear ERβ was expressed in 89.66% and cytoplas-
mic ERβ was expressed in 77.59% [17].
As expression of ERβ declines during tumorigenesis of
breast, colon and prostate cancer, this receptor has been
proposed to act as a tumor suppressor [9–11, 34]. ERβ
expression is highest in normal ovarian tissue whereas it
decreases during dedifferentiation processes [16]. This is
in line with our data showing a significantly lower ex-
pression of nuclear ERβ in G3 ovarian cancers than in
better differentiated tumors. In vitro, we showed re-
duced proliferation and migration of ovarian cancer cells
after overexpression of ERβ as well as increased rates of
apoptosis [12]. Moreover, we found a significant
growth-inhibition of ovarian cancer cells by treatment
with specific ERβ-agonists [13]. Thus, these data support
the tumor suppressive role of ERβ in ovarian cancer.
In our study PR expression was significantly higher in
early stage ovarian cancers than in cancers with FIGO
stages III and IV (p = 0.0027). Moreover, we showed a
significantly higher expression of PR in tumors without
Fig. 2 Expression of nuclear ERβ in G2 and G3 graded ovarian
cancer. Shown are the mean values of the immunoreactivity scores
(p < 0.05). n (G2) = 64, n (G3) = 109
Table 4 Correlation of nuclear ERβ expression in ovarian cancer with expression of ovarian cancer markers, cancer-associated genes
and steroid hormone receptors
CA125 CEA CA72–4 EGFR HER2 Ki-67 P53 ERα PR
All Spearman r −0.041 0.31 0.216 0.054 0.045 −0.084 0.101 0.086 0.006
95% CI −0.198
- 0.117
0.16
- 0.447
0.06
- 0.362
−0.107
- 0.213
− 0.114
- 0.201
− 0.246
- 0.083
− 0.058
- 0.255
− 0.073
- 0.240
− 0.154
- 0.166
P value n.s. < 0.0001 0.0057 n.s. n.s. n.s. n.s. n.s. n.s.
Serous Spearman r 0.051 0.345 0.264 0.089 0.098 −0.061 0.067 0.095 0.011
95% CI −0.129 - 0.227 0.177
- 0.493
0.089
- 0.423
−0.0940 - 0.266 −0.083 - 0.274 − 0.245 - 0.128 −0.113 - 0.242 − 0.084 - 0.269 −0.170 - 0.193
P value n.s. < 0.0001 0.0026 n.s. n.s. n.s. n.s. n.s. n.s.
Correlation of nuclear ERβ expression with expression of ovarian cancer markers CA125, CEA, CA72–4, and with EGFR, HER2, Ki-67, P53, ERα and PR were
calculated for all ovarian cancers (“all”) and serous ovarian cancers (“serous”) using the Spearman correlation coefficient. P-values below 0.05 were
considered statistically significant (significant results were indicated by using bold font)
CI confidence interval
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invasion of lymphatic vessels compared to cancers that
did not invade lymphatic vessels. In line with data pub-
lished earlier, progression-free survival of patients with
PR-expressing tumors was significantly longer compared
to those with tumors not expressing PR [5, 28, 35]. This
could be explained by an induction of apoptosis by PR
activation in ovarian cancer [5]. Multiple in vitro studies
have shown that increased PR expression could promote
the progesterone-induced inhibition of DNA synthesis,
cell division and proliferation in ovarian cancer cells
[35, 36]. Moreover, PR is transactivated by ERα and
PR expression may be a biomarker of improved prog-
nosis because it indicates a functionally intact ER
pathway and less aggressive tumor behavior [5].
With regard to overall survival and progression-free
survival, data from literature remain inconclusive. In our
study, patients with tumors expressing cytoplasmic ERβ
had a significant benefit in overall survival compared to
those with tumors not expressing this form of ERβ. A
recent study revealed that ERβ-positive nuclear staining
was associated with decreased progression-free survival
(hazard ratio (HR) 1.69; 95% CI 0.91–3.15; p = 0.096)
and decreased overall survival (HR 1.91; 95% CI 0.94–
3.89; p = 0.075) [37]. In the study by De Stefano et al. ex-
pression of cytoplasmic ERβ predicted poor clinical out-
come in serous ovarian cancer. However, the study was
smaller with 58 included ovarian cancer cases and only
serous cases were included [17].
CA125 is overexpressed in the majority of serous ovarian
cancers, the most common histological subtype [18]. We
found a high correlation between the expression of ERα and
the expression of CA125, which is in line with the findings
of Sylvia et al. [38]. CA125 interacts with cell-adhesion regu-
lators mesothelin, galectin-1 and E-cadherin and β-catenin
[18, 19] and is involved in promotion of proliferation and
migration [20]. Park et al. found an ERα-dependent,
estrogen-induced suppression of expression and promoter
activity of E-cadherin in ovarian cancer cells, whereas
epithelial-mesenchymal transition-associated transcription
factors, Snail and Slug, were significantly up-regulated [39].
Table 5 Correlation of cytoplasmic ERβ with expression of cancer-associated genes and steroid hormone receptors
CA125 CEA CA72–4 EGFR HER2 Ki-67 P53 ERα ERβ (n) PR
All Spearman r 0.073 0.036 0.026 0.262 0.089 −0.012 0.037 −0.049 −0.085 0.131
95% CI −0.086
− 0.227
−0.122
− 0.193
−0.132
- 0.183
0.106
- 0.405
−0.069
- 0.243
− 0.175
- 0.152
−0.121
- 0.194
− 0.205
- 0.109
−0.238
- 0.073
− 0.029
- 0.284
p value n.s. n.s. n.s. 0.0009 n.s. n.s. n.s. n.s. n.s. n.s.
Serous Spearman r −0.007 0.041 −0.026 0.238 0.020 0.174 0.083 −0.109 −0.078 0.202
95% CI −0.183
- 0.17
−0.138
- 0.216
− 0.202
− 0.152
0.06
− 0.402
−0.158
- 0.197
− 0.010
- 0.346
−0.095
- 0.257
− 0.281
- 0.07
−0.252
- 0.099
0.023–0.3699
p value n.s. n.s. n.s. 0.0075 n.s. n.s. n.s. n.s. n.s. 0.0231
Correlations of cytoplasmic ERβ expression with expression of ovarian cancer markers CA125, CEA, CA72–4 and with EGFR, HER2, Ki-67, P53, ERα, nuclear ERβ (n)
and PR were calculated for all ovarian cancers (“all”) and serous ovarian cancers (“serous”) using the Spearman correlation coefficient. P-values below 0.05 were
considered statistically significant (significant results were indicated by using bold font)
CI confidence interval
Fig. 3 Kaplan Meier survival analysis in ovarian cancer in relation to cytoplasmic ERβ expression. Overall survival of patients with absent
expression of cytoplasmic ERβ was compared to survival of patients with cytoplasmic ERβ expression (p = 0.0362). The chi-square statistic of the
log-rank was used to investigate differences between survival curves. P-values below 0.05 were considered statistically significant
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Thus, this possible interaction between CA125 and ERα in
regulation of cell adhesion should be elucidated in future
studies. Also CEA has a regulative function in cell adhesion
and thus an influence on metastasis of cancer cells has been
suggested [21]. Another antigen selectively expressed in
ovarian cancer is CA72–4. As it is highly detectable in all
ovarian cancer subtypes it is another effective tumor marker
in ovarian cancer [22]. However, its function in carcinogen-
esis of ovarian cancer is still unknown. We were able to
show a high correlation between the expression of nuclear
ERβ and CEA as well as CA72–4. Moreover, we observed a
significant correlation between expression of ERα and PR
(Additional file 2), which is in line with studies published
earlier [28, 40].
As discussed above, the role of ERβ as a tumor sup-
pressor in ovarian cancers is still controversial. Our data
and those published by others clearly suggest a contra-
dictory role of nuclear and cytoplasmic ERβ. Our results
demonstrating an improvement of overall survival for
patients with ovarian cancers expressing cytoplasmic
ERβ corroborate a tumor suppressive role of ERβ. In
contrast, nuclear expression of this receptor previously
has been reported to shorten progression-free survival
[37]. This is in accordance with our finding that expres-
sion of nuclear ERβ is associated with tumor markers
CEA and CA72–4. Different binding partners depending
on the subcellular location of ERβ might explain these
effects [23]. Our data suggest that future studies should
further assess the different roles of nuclear and cytoplas-
mic ERβ in ovarian cancer as previous controversial re-
sults might be due to a distinct function of ERβ
depending on its location.
Fig. 4 Kaplan Meier survival analysis of progression-free survival (PFS). a PFS in all ovarian cancer cases in relation to PR expression. PFS of
patients without expression of PR was compared to survival of patients with PR expression (p = 0.0261). The chi-square statistic of the log-rank
was used to investigate differences between survival curves. P-values below 0.05 were considered statistically significant. PFS of those patients
whose tumors express PR (IRS≥ 1) compared to those with PR negative tumors (IRS 0); b PFS of ovarian cancer patients whose tumors expressing
Ki-67 compared to those with low or absent Ki-67 expression (p = 0.0134)
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Conclusions
To our knowledge, we are the first to show a correlation
between nuclear ERβ and CEA as well as CA72–4 ex-
pression in ovarian cancer. Moreover, our data support
the role of ERβ as a tumor suppressor in ovarian cancer,
as our survival analyses show a significant benefit in
overall survival of patients with tumors expressing cyto-
plasmic ERβ. Further studies will be necessary to exam-
ine the relevance of our data in the clinical setting.
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